MedTrace Logo

Cellular Therapy With Cord Blood Cells

NCT00427557 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-05-28

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if giving umbilical cord blood along with standard stem cells after high-dose chemotherapy will improve the response to a stem cell transplant. The safety of this treatment will also be studied.

Conditions

Interventions

DRUG

Fludarabine

30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).

DRUG

Melphalan

140 mg/m\^2 by vein for 1 Day (Day -7).

PROCEDURE

Umbilical Cord Blood

1 UCB Unit by vein on Day -5.

DRUG

Rituximab

375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).

OTHER

Peripheral Blood Stem Cell Infusion

Infusion of blood stem cells on Day 0.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Partow Kebriaei, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427557 on ClinicalTrials.gov